Evidence map›Paper›PMID 34655027›Full record

ReviewCurrent hematologic malignancy reports2021

Challenges in Chronic Myeloid Leukemia Management in South America.

Katia B Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A M Funke, Virginia Abello Polo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katia B PagnanoCentro de Hematologia E Hemoterapia, Universidade Estadual de Campinas, Campinas, SP, Brazil. kborgia@unicamp.br.
Ana Ines VarelaHospital J.M. Ramos Mejía, Sanatorio Las Lomas, Buenos Aires, Argentina.
Carolina PavlovskyFUNDALEU, Buenos Aires, Argentina.
Israel BenditLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM/31), Department of Hematology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Vaneuza A M FunkeComplexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Virginia Abello PoloFacultad de Medicina, Fundación Universitaria de Ciencias de La Salud. Servicio de Hematología, Hospital de San José. Servicio de Hematología, Clínica del Country, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewChronic myeloid leukemia (CML) management in developing countries has improved in the last years, but the availability of therapeutic resources, monitoring, reimbursement, and financial issues may be a challenge and interfere with the best practices and results of CML treatment. This review points out the main challenges in CML management in South America. RECENT

findingsIn this review, we describe the access to tyrosine kinase inhibitors and monitoring in different countries of South America. We also address the ongoing discontinuation trials, the progress, and limitations of hematopoietic stem cell transplantation in the last years. There are still many challenges for achieving the best outcomes for CML patients in South America. The continuous efforts to provide continuous education, access to tyrosine kinase inhibitors, and monitoring, providing reference centers for CML management and hematopoietic stem cell transplantation may improve patients' outcomes.

Indexed as

Antineoplastic AgentsDisease ManagementHematopoietic Stem Cell TransplantationHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsSouth AmericaAntineoplastic AgentsProtein Kinase InhibitorsChronic myeloid leukemiaHematopoietic stem cell transplantationManagementMonitoringTreatment-free remissionTyrosine kinase inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.